 MENLO PARK, Calif.--BUSINESS WIRE--Intersect ENT, Inc. Nasdaq: XENT, a global ear, nose and throat ENT medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Overview Entered into a definitive agreement with Medtronic, in which Medtronic will acquire all outstanding shares of Intersect ENT. Revenue of 27.3 million in the second quarter of 2021, up 180, compared to 9.8 million i 